ATE188708T1 - Antikörperderivate - Google Patents
AntikörperderivateInfo
- Publication number
- ATE188708T1 ATE188708T1 AT92810633T AT92810633T ATE188708T1 AT E188708 T1 ATE188708 T1 AT E188708T1 AT 92810633 T AT92810633 T AT 92810633T AT 92810633 T AT92810633 T AT 92810633T AT E188708 T1 ATE188708 T1 AT E188708T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- antibodies derivatives
- antibodies
- derivatives
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919118013A GB9118013D0 (en) | 1991-08-21 | 1991-08-21 | Monoclonal antibodies and their use |
| GB929204514A GB9204514D0 (en) | 1992-03-02 | 1992-03-02 | Monoclonal antibodies and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE188708T1 true ATE188708T1 (de) | 2000-01-15 |
Family
ID=26299429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92810633T ATE188708T1 (de) | 1991-08-21 | 1992-08-18 | Antikörperderivate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5562903A (de) |
| EP (1) | EP0528767B1 (de) |
| JP (1) | JP3474592B2 (de) |
| AT (1) | ATE188708T1 (de) |
| CA (1) | CA2076432C (de) |
| DE (1) | DE69230545T2 (de) |
| DK (1) | DK0528767T3 (de) |
| ES (1) | ES2145004T3 (de) |
| GR (1) | GR3032944T3 (de) |
| PT (1) | PT528767E (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0644947T3 (da) * | 1992-05-22 | 1999-11-01 | Novartis Ag | Anti-idiotypiske monoklonale antistoffer mod det Lewis Y-specifikke monoklonale antistof BR55-2 og deres anvendelser |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| EP0781847A1 (de) * | 1995-11-06 | 1997-07-02 | MERCK PATENT GmbH | Humanisierter monoklonaler Antikörper |
| AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| CN1360596A (zh) * | 1999-02-12 | 2002-07-24 | 遗传研究所有限公司 | 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法 |
| AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7390885B2 (en) | 2001-11-26 | 2008-06-24 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
| AT413486B (de) | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| AT413487B (de) | 2002-08-12 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung von antikörpern gegen ein tumor-assoziiertes antigen |
| AT500648B1 (de) | 2002-08-12 | 2010-03-15 | Igeneon Krebs Immuntherapie | Set zur behandlung von krebspatienten |
| US7780992B2 (en) * | 2002-12-08 | 2010-08-24 | Tareq Abduljalil Albahri | Antiviral medicament |
| TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| JP2008505943A (ja) * | 2004-07-14 | 2008-02-28 | イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト | グリコシル化抗体 |
| WO2006081171A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| CA2596833C (en) * | 2005-02-03 | 2016-04-12 | Antitope Limited | Human antibodies and proteins |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| MX2008014842A (es) | 2006-05-25 | 2009-02-17 | Glaxo Group Ltd | Anticuerpos humanizados contra interleuquina-18 modificados. |
| BRPI0712850A8 (pt) * | 2006-06-07 | 2018-05-02 | Bioalliance Cv | anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos |
| EP1878747A1 (de) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-hergestellte Antikörper |
| AU2007285763B2 (en) * | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| AT504231A1 (de) | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| US8465741B2 (en) * | 2006-12-20 | 2013-06-18 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
| CA3184105A1 (en) * | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| CN105732813A (zh) | 2007-12-18 | 2016-07-06 | 生物联合公司 | 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法 |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| WO2009086539A2 (en) * | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| JP5818688B2 (ja) * | 2009-01-08 | 2015-11-18 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | 核酸増幅反応の効率を改善するための方法および組成物 |
| WO2010108048A2 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物 |
| AU2011252851B2 (en) * | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| EP2407487A1 (de) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispezifische modulare Antikörper |
| JP2012067106A (ja) * | 2011-10-14 | 2012-04-05 | Greenovation Biotech Gmbh | グリコシル化抗体 |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| WO2017216724A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
| CN109266656B (zh) * | 2018-10-10 | 2021-02-19 | 江苏集萃药康生物科技股份有限公司 | 一种PD1人源化BALB/c小鼠模型的构建方法及其应用 |
| GB201910899D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0256654B1 (de) * | 1986-07-07 | 1996-09-18 | Centocor, Inc. | Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen |
| US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
| US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE4006308A1 (de) * | 1990-02-28 | 1991-08-29 | Sandoz Ag | Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom |
| DE4025499A1 (de) * | 1990-08-11 | 1992-02-13 | Sandoz Ag | Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen |
-
1992
- 1992-08-18 PT PT92810633T patent/PT528767E/pt unknown
- 1992-08-18 ES ES92810633T patent/ES2145004T3/es not_active Expired - Lifetime
- 1992-08-18 EP EP92810633A patent/EP0528767B1/de not_active Expired - Lifetime
- 1992-08-18 DK DK92810633T patent/DK0528767T3/da active
- 1992-08-18 AT AT92810633T patent/ATE188708T1/de active
- 1992-08-18 DE DE69230545T patent/DE69230545T2/de not_active Expired - Lifetime
- 1992-08-19 CA CA002076432A patent/CA2076432C/en not_active Expired - Lifetime
- 1992-08-20 JP JP22136192A patent/JP3474592B2/ja not_active Expired - Lifetime
-
1993
- 1993-04-22 US US08/053,171 patent/US5562903A/en not_active Expired - Lifetime
-
2000
- 2000-03-10 GR GR20000400640T patent/GR3032944T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05336989A (ja) | 1993-12-21 |
| GR3032944T3 (en) | 2000-07-31 |
| CA2076432C (en) | 2003-10-21 |
| US5562903A (en) | 1996-10-08 |
| ES2145004T3 (es) | 2000-07-01 |
| CA2076432A1 (en) | 1993-02-22 |
| PT528767E (pt) | 2000-06-30 |
| DK0528767T3 (da) | 2000-04-17 |
| DE69230545D1 (de) | 2000-02-17 |
| JP3474592B2 (ja) | 2003-12-08 |
| DE69230545T2 (de) | 2000-07-06 |
| EP0528767A1 (de) | 1993-02-24 |
| EP0528767B1 (de) | 2000-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2145004T3 (es) | Derivados de anticuerpos. | |
| ATE123652T1 (de) | Antigene. | |
| IT9068053A0 (it) | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego | |
| ES520692A0 (es) | Un procedimiento de preparacion de conjugados inmunoenzimaticos. | |
| DE3783277D1 (de) | Monoklonaler antikoerper gegen humanes lungenkarzinom. | |
| EP0552296A4 (en) | Mouse monoclonal antibodies | |
| OA08485A (fr) | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas. | |
| AU7198291A (en) | Human monoclonal antibodies against rabies viruses, the production and the use thereof | |
| PT796280E (pt) | Anticorpo monoclonal 3h1 anti-idiotipico dos murinos | |
| NO870476D0 (no) | Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater. | |
| EP0198086A4 (de) | Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikörpern, deren herstellung und antivirale menschliche monoklonale antikörper. | |
| EP0341684A3 (en) | Human monoclonal antibody, hybridoma producing the same and pharmaceutical | |
| AU584690B2 (en) | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma | |
| DE3485712D1 (de) | Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren. | |
| FI92716C (fi) | Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen | |
| DE69119591D1 (de) | Das von mca-28a32 erkannte antigen | |
| AU2070688A (en) | Antigen recognized by mca 16-88 | |
| DE3584280D1 (de) | Monoklonaler antikoerper gegen menschlichen krebs. | |
| DE69232140D1 (de) | Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind | |
| EP0334076A3 (en) | Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same | |
| NO924803L (no) | Tumor-relatert monoklonalt antistoff 88bv59 | |
| DE3882066D1 (de) | Monoclonaler antikoerper gegen menschliches lungenadenokarzinom. | |
| FI924818A7 (fi) | Ihmiskäyttöön sopivat CDR-oksastetut anti-ICAM-1-vasta-aineet, menetel mät niiden valmistamiseksi ja niiden käyttö | |
| FI883765L (fi) | Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden. | |
| NO952506L (no) | Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |